Picture

Questions?

+1-866-353-3335

SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare
Free Samples
Vaccines

PUBLISHER: MarketsandMarkets | PRODUCT CODE: 1384226

Cover Image

PUBLISHER: MarketsandMarkets | PRODUCT CODE: 1384226

Vaccines Market by Technology, Type, Disease, Route of Administration, End user & Region - Global Forecast to 2028

PUBLISHED:
PAGES: 371 Pages
DELIVERY TIME: 1-2 business days
REQUEST FREE SAMPLE
REQUEST CUSTOMIZATION
SELECT AN OPTION
PDF (Single User License)
USD 4950
PDF (5-user License)
USD 6650
PDF (Corporate License)
USD 8150
PDF (Global License)
USD 10000

Add to Cart

Description

Table of Contents

Report Description

Scope of the Report
Years Considered for the Study2021-2028
Base Year2022
Forecast Period2023-2028
Units ConsideredValue (USD) Billion
SegmentsBy Technology, By Type, By Disease Indication, By Route of Administration, By End User
Regions coveredNorth America, Europe, Asia Pacific, Latin America, Middle East and Africa.

The global vaccines market size is projected to reach USD 93.8 billion by 2028 from USD 77.6 billion in 2023, at a CAGR of 3.9% during the forecast period. Factors such as high incidence of contagious diseases, innovation in vaccine technology, governmental support & substantial funding for vaccine development, growing vaccination initiatives and strong focus on investing and launching innovative vaccines.

"The conjugate vaccines segment held the dominant share in the vaccines market"

Based on technology, the global vaccines market is segmented into inactivated & subunit vaccines, live attenuated vaccines, toxoid vaccines, viral vector vaccines, recombinant vaccines and conjugate vaccines. The conjugate vaccines segment is anticipated to grow at significant CAGR. Growing governmental support coupled with investment by companies in the field of conjugate vaccine development, increasing collaboration between public and private sectors are likely to have positive impact on the growth of the market.

"Pneumococcal segment accounted for the largest share of the disease indication segment in 2022."

Based on disease indication, the vaccines market is segmented into, combination vaccines, HPV, meningococcal disease, herpes zoster, rotavirus, MMR, pneumococcal disease, influenza, varicella, hepatitis, DTP, polio, and other disease indications. In 2022, the pneumococcal segment accounted for the largest share of the vaccines market. The segment held the dominant share in the market owing to various factors such increased pneumococcal disease cases, with a rising government investment in vaccination programs.

"Asia Pacific region is likely to grow at a faster pace in the vaccines market."

The vaccines market region is segmented into North America, Europe, Asia Pacific, Latin America, Middle East and the Africa. Asia Pacific region is anticipated to grow at a significant CAGR during the forecast period. The growth of the region is majorly driven by companies that are upping their investments in Asia-Pacific region, benefiting from increased government support for vaccine development, rising healthcare expenditure in Asian countries, emergence & re-emergence of contagious disease and rising disposable income.

The primary interviews conducted for this report can be categorized as follows:

  • By Respondent: Supply Side- 80%, and Demand Side - 20%
  • By Designation (Supply Side): Managers - 45%, CXOs & Directors - 30%, Executives- 25%
  • By Region: North America -40%, Europe -25%, Asia-Pacific -20%, Latin America -10%, Middle East-4% and Africa -1%

List of Companies Profiled in the Report:

  • GSK plc (UK)
  • Merck & Co., Inc. (US)
  • Pfizer, Inc. (US)
  • Sanofi (France)
  • CSL (Australia)
  • Emergent (US)
  • Johnson & Johnson Services Inc. (US)
  • AstraZeneca (UK)
  • Serum Institute of India Pvt. Ltd. (India)
  • Bavarian Nordic (Denmark)
  • Mitsubishi Tanabe Pharma Corporation (Japan)
  • Daiichi Sankyo Company, Limited (Japan)
  • Panacea Biotec (India)
  • Biological E. Limited (India)
  • Bharat Biotech (India)
  • Novavax (US)
  • Inovio Pharmaceuticals (US)
  • Sinovac (China)
  • Incepta Pharmaceuticals (Bangladesh)
  • Valneva SE (France),
  • VBI Vaccines Inc. (US)
  • Bio Farma (Indonesia)
  • FSUE NPO Microgen (Russia)
  • Zhi fei Biological (China)
  • Indian Immunologicals Ltd (India)

Research Coverage:

This report provides a detailed picture of the vaccines market. It aims at estimating the size and future growth potential of the market across different segments such as the technology, type, disease indication, route of administration, end-user and region. The report also includes an in-depth competitive analysis of the key market players along with their company profiles recent developments and key market strategies.

Key Benefits of Buying the Report:

The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall vaccines market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, opportunities, and challenges.

The report provides insights on the following pointers:

  • Analysis of key drivers (strong emphasis on investment and launch of novel vaccines, rising prevalence of infectious disease, expanding immunization programs, advancements in vaccine technology and robust government support & funding for the development of vaccines), restraints (High development cost, patent expiry ), opportunities (Increased focus on therapeutic vaccines, robust & strong pipeline) and challenges (stringnent regulatory processes, vaccine supply shortage, frequent product recall) are influencing the growth of clinical trial supplies market.
  • Product Development/Innovation: Detailed insights on newly launched products of the vaccines market.
  • Market Development: Comprehensive information about lucrative markets - the report analyses the vaccines market across varied regions.
  • Market Diversification: Exhaustive information about new services, untapped geographies, recent developments, and investments in the vaccines market.
  • Pipeline Analysis: Comprehensive information about products under clinical trials.
  • Competitive Assessment: In-depth assessment of market shares, growth strategies, and service offerings of leading players include GSK plc (UK), Merck & Co., Inc. (US), Pfizer, Inc. (US), Sanofi (France), CSL (Australia), Emergent (US), Johnson & Johnson Services Inc. (US), AstraZeneca (UK), Serum Institute of India Pvt. Ltd. (India), Bavarian Nordic (Denmark).
Show more
Product Code: PH 6528

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 STUDY OBJECTIVES
  • 1.2 MARKET DEFINITION
  • 1.3 INCLUSIONS & EXCLUSIONS
  • 1.4 MARKET SCOPE
    • 1.4.1 MARKETS COVERED
    • 1.4.2 REGIONS COVERED
    • 1.4.3 YEARS CONSIDERED
    • 1.4.4 CURRENCY CONSIDERED
  • 1.5 RESEARCH LIMITATIONS
  • 1.6 STAKEHOLDERS
  • 1.7 SUMMARY OF CHANGES
  • 1.8 RECESSION IMPACT: VACCINES MARKET

2 RESEARCH METHODOLOGY

  • 2.1 RESEARCH DATA
  • 2.2 RESEARCH APPROACH
    • FIGURE 1 RESEARCH DESIGN
    • 2.2.1 SECONDARY DATA
    • 2.2.2 PRIMARY DATA
    • FIGURE 2 BREAKDOWN OF PRIMARIES
      • 2.2.2.1 Primary insights
    • FIGURE 3 KEY INSIGHTS FROM PRIMARY EXPERTS
  • 2.3 MARKET SIZE ESTIMATION
    • FIGURE 4 MARKET SIZE ESTIMATION: VACCINES MARKET, 2022
    • FIGURE 5 TOTAL REVENUE: VACCINES MARKET
    • FIGURE 6 REVENUE SHARE OF PFIZER INC., 2022
    • 2.3.1 SEGMENTAL ASSESSMENT
    • FIGURE 7 TOP-DOWN APPROACH
  • 2.4 GROWTH RATE ASSUMPTIONS
    • FIGURE 8 CAGR PROJECTION: VACCINES MARKET
    • FIGURE 9 GROWTH ANALYSIS OF DRIVERS, RESTRAINTS, CHALLENGES, AND OPPORTUNITIES
  • 2.5 STUDY ASSUMPTIONS
  • 2.6 MARKET BREAKDOWN AND DATA TRIANGULATION
    • FIGURE 10 DATA TRIANGULATION METHODOLOGY
  • 2.7 RISK ASSESSMENT
  • 2.8 IMPACT OF RECESSION IN VACCINES MARKET
    • TABLE 1 GLOBAL INFLATION RATE PROJECTION, 2024-2028 (% GROWTH)
    • TABLE 2 US HEALTH EXPENDITURE, 2019-2022 (USD MILLION)
    • TABLE 3 US HEALTH EXPENDITURE, 2023-2027 (USD MILLION)

3 EXECUTIVE SUMMARY

    • FIGURE 11 VACCINES MARKET, BY TECHNOLOGY, 2023 VS. 2028 (USD BILLION)
    • FIGURE 12 VACCINES MARKET, BY TYPE, 2023 VS. 2028 (USD BILLION)
    • FIGURE 13 VACCINES MARKET, BY DISEASE INDICATION, 2023 VS. 2028 (USD BILLION)
    • FIGURE 14 VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2023 VS. 2028 (USD BILLION)
    • FIGURE 15 VACCINES MARKET, BY END USER, 2023 VS. 2028 (USD BILLION)
    • FIGURE 16 GEOGRAPHICAL SNAPSHOT OF VACCINES MARKET

4 PREMIUM INSIGHTS

  • 4.1 VACCINES MARKET OVERVIEW
    • FIGURE 17 RISING PREVALENCE OF INFECTIOUS DISEASES TO DRIVE MARKET
  • 4.2 NORTH AMERICA: VACCINES MARKET, BY TECHNOLOGY AND COUNTRY, 2022
    • FIGURE 18 M-RNA VACCINES AND US ACCOUNTED FOR LARGEST SHARE OF NORTH AMERICAN VACCINES MARKET IN 2022
  • 4.3 VACCINES MARKET, BY TECHNOLOGY, 2023 VS. 2028
    • FIGURE 19 M-RNA VACCINES TO DOMINATE MARKET IN 2028
  • 4.4 GEOGRAPHICAL GROWTH OPPORTUNITIES: VACCINES MARKET
    • FIGURE 20 ASIA PACIFIC TO REGISTER HIGHEST GROWTH RATE DURING FORECAST PERIOD

5 MARKET OVERVIEW

  • 5.1 INTRODUCTION
  • 5.2 MARKET DYNAMICS
    • FIGURE 21 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES: VACCINES MARKET
    • TABLE 4 IMPACT ANALYSIS: VACCINES MARKET
    • 5.2.1 DRIVERS
      • 5.2.1.1 Strong emphasis on launch of novel vaccines
      • 5.2.1.2 Rising prevalence of infectious diseases
    • FIGURE 22 INCIDENCE OF TUBERCULOSIS IN US, 2017-2021
      • 5.2.1.3 Increasing number of immunization programs
      • 5.2.1.4 Advancements in vaccine technology
      • 5.2.1.5 Robust government support and funding for vaccine development
    • TABLE 5 NIH FUNDING FOR VACCINE RESEARCH, 2020-2024 (USD MILLION)
    • 5.2.2 RESTRAINTS
      • 5.2.2.1 High cost of vaccine development
    • 5.2.3 OPPORTUNITIES
      • 5.2.3.1 Increased focus on therapeutic vaccines
      • 5.2.3.2 Extensive R&D for vaccines and increased investments in clinical trials
    • 5.2.4 CHALLENGES
      • 5.2.4.1 Stringent regulatory processes
      • 5.2.4.2 Frequent product recalls
  • 5.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES
    • FIGURE 23 REVENUE SHIFTS AND NEW REVENUE POCKETS FOR VACCINE PROVIDERS
  • 5.4 PRICING ANALYSIS
    • 5.4.1 AVERAGE SELLING PRICE OF PRODUCTS, BY KEY PLAYERS
    • TABLE 6 AVERAGE SELLING PRICE OF PEDIATRIC VACCINES
    • TABLE 7 AVERAGE SELLING PRICE OF ADULT VACCINES
    • 5.4.2 AVERAGE SELLING PRICE, BY PRODUCT TYPE
    • TABLE 8 AVERAGE SELLING PRICE OF CONJUGATE VACCINES
    • TABLE 9 AVERAGE SELLING PRICE OF RECOMBINANT VACCINES
    • TABLE 10 AVERAGE SELLING PRICE OF INACTIVATED & SUBUNIT VACCINES
    • TABLE 11 AVERAGE SELLING PRICE OF LIVE ATTENUTAED VACCINES
    • TABLE 12 AVERAGE SELLING PRICE OF TOXOID VACCINES
    • TABLE 13 AVERAGE SELLING PRICE OF M-RNA VACCINES
    • 5.4.3 AVERAGE SELLING PRICE TREND
  • 5.5 TECHNOLOGY ANALYSIS
  • 5.6 VALUE CHAIN ANALYSIS
    • FIGURE 24 VALUE CHAIN ANALYSIS: RAW MATERIAL AND MANUFACTURING PHASES TO CONTRIBUTE MAXIMUM VALUE
  • 5.7 PIPELINE ANALYSIS
    • FIGURE 25 CLINICAL TRIALS IN VACCINES MARKET
    • FIGURE 26 VACCINES MARKET IN CLINICAL TRIALS, BY DISEASE INDICATION
    • TABLE 14 PIPELINE PRODUCTS UNDER PHASE-2 AND PHASE-3 CLINICAL TRIALS
    • 5.7.1 KEY PIPELINE PRODUCTS
    • TABLE 15 KEY PIPELINE VACCINES: GSK PL
    • TABLE 16 KEY PIPELINE VACCINES: MERCK & CO., INC.
    • TABLE 17 KEY PIPELINE VACCINES: PFIZER, INC.
    • TABLE 18 KEY PIPELINE VACCINES: SANOFI S.A.
  • 5.8 ECOSYSTEM MARKET/MAP
    • FIGURE 27 ECOSYSTEM MARKET/MAP
    • TABLE 19 ROLE IN ECOSYSTEM: VACCINES MARKET
  • 5.9 REGULATORY ANALYSIS
    • 5.9.1 REGULATORY LANDSCAPE FOR VACCINES
    • 5.9.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
    • TABLE 20 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
    • TABLE 21 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
    • TABLE 22 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
    • TABLE 23 LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
    • TABLE 24 MIDDLE EAST: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
    • TABLE 25 AFRICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • 5.10 PORTER'S FIVE FORCES ANALYSIS
    • TABLE 26 PORTER'S FIVE FORCES ANALYSIS
    • 5.10.1 THREAT OF NEW ENTRANTS
    • 5.10.2 THREAT OF SUBSTITUTES
    • 5.10.3 BARGAINING POWER OF SUPPLIERS
    • 5.10.4 BARGAINING POWER OF BUYERS
    • 5.10.5 INTENSITY OF COMPETITIVE RIVALRY
  • 5.11 PATENT ANALYSIS
    • FIGURE 28 PATENT APPLICATIONS FOR VACCINES, SEPTEMBER 2013-SEPTEMBER 2023
    • TABLE 27 INDICATIVE LIST OF PATENTS IN VACCINES MARKET
  • 5.12 KEY CONFERENCES & EVENTS
    • TABLE 28 DETAILED LIST OF KEY CONFERENCES & EVENTS, 2023-2024
  • 5.13 KEY STAKEHOLDERS & BUYING CRITERIA
    • 5.13.1 KEY STAKEHOLDERS IN BUYING PROCESS
    • FIGURE 29 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF VACCINES
    • 5.13.2 KEY BUYING CRITERIA
    • FIGURE 30 KEY BUYING CRITERIA FOR END USERS IN VACCINES MARKET

6 VACCINES MARKET, BY TECHNOLOGY

  • 6.1 INTRODUCTION
    • TABLE 29 VACCINES MARKET, BY TECHNOLOGY, 2021-2028 (USD BILLION)
  • 6.2 CONJUGATE VACCINES
    • 6.2.1 INCREASING PUBLIC-PRIVATE PARTNERSHIPS TO DRIVE MARKET
    • TABLE 30 VACCINES MARKET FOR CONJUGATE VACCINES, BY REGION, 2021-2028 (USD BILLION)
    • TABLE 31 NORTH AMERICA: VACCINES MARKET FOR CONJUGATE VACCINES, BY COUNTRY, 2021-2028 (USD BILLION)
    • TABLE 32 EUROPE: VACCINES MARKET FOR CONJUGATE VACCINES, BY COUNTRY, 2021-2028 (USD BILLION)
    • TABLE 33 ASIA PACIFIC: VACCINES MARKET FOR CONJUGATE VACCINES, BY COUNTRY, 2021-2028 (USD BILLION)
    • TABLE 34 LATIN AMERICA: VACCINES MARKET FOR CONJUGATE VACCINES, BY COUNTRY, 2021-2028 (USD BILLION)
  • 6.3 RECOMBINANT VACCINES
    • 6.3.1 LESSER POST-VACCINATION REACTIONS AND REDUCED NEED FOR BOOSTER DOSES TO DRIVE MARKET
    • TABLE 35 EXAMPLES OF RECOMBINANT VACCINES
    • TABLE 36 VACCINES MARKET FOR RECOMBINANT VACCINES, BY REGION, 2021-2028 (USD BILLION)
    • TABLE 37 NORTH AMERICA: VACCINES MARKET FOR RECOMBINANT VACCINES, BY COUNTRY, 2021-2028 (USD BILLION)
    • TABLE 38 EUROPE: VACCINES MARKET FOR RECOMBINANT VACCINES, BY COUNTRY, 2021-2028 (USD BILLION)
    • TABLE 39 ASIA PACIFIC: VACCINES MARKET FOR RECOMBINANT VACCINES, BY COUNTRY, 2021-2028 (USD BILLION)
    • TABLE 40 LATIN AMERICA: VACCINES MARKET FOR RECOMBINANT VACCINES, BY COUNTRY, 2021-2028 (USD BILLION)
  • 6.4 INACTIVATED & SUBUNIT VACCINES
    • 6.4.1 EASE OF STORAGE AND TRANSPORTATION TO DRIVE MARKET
    • TABLE 41 EXAMPLES OF INACTIVATED & SUBUNIT VACCINES
    • TABLE 42 VACCINES MARKET FOR INACTIVATED & SUBUNIT VACCINES, BY REGION, 2021-2028 (USD BILLION)
    • TABLE 43 NORTH AMERICA: VACCINES MARKET FOR INACTIVATED & SUBUNIT VACCINES, BY COUNTRY, 2021-2028 (USD BILLION)
    • TABLE 44 EUROPE: VACCINES MARKET FOR INACTIVATED & SUBUNIT VACCINES, BY COUNTRY, 2021-2028 (USD BILLION)
    • TABLE 45 ASIA PACIFIC: VACCINES MARKET FOR INACTIVATED & SUBUNIT VACCINES, BY COUNTRY, 2021-2028 (USD BILLION)
    • TABLE 46 LATIN AMERICA: VACCINES MARKET FOR INACTIVATED & SUBUNIT VACCINES, BY COUNTRY, 2021-2028 (USD BILLION)
  • 6.5 LIVE ATTENUATED VACCINES
    • 6.5.1 HIGH COST OF STORAGE AND LIMITED FINANCIAL RESOURCES OF DISTRIBUTORS TO LIMIT MARKET
    • TABLE 47 EXAMPLES OF LIVE ATTENUATED VACCINES
    • TABLE 48 VACCINES MARKET FOR LIVE ATTENUATED VACCINES, BY REGION, 2021-2028 (USD BILLION)
    • TABLE 49 NORTH AMERICA: VACCINES MARKET FOR LIVE ATTENUATED VACCINES, BY COUNTRY, 2021-2028 (USD BILLION)
    • TABLE 50 EUROPE: VACCINES MARKET FOR LIVE ATTENUATED VACCINES, BY COUNTRY, 2021-2028 (USD BILLION)
    • TABLE 51 ASIA PACIFIC: VACCINES MARKET FOR LIVE ATTENUATED VACCINES, BY COUNTRY, 2021-2028 (USD BILLION)
    • TABLE 52 LATIN AMERICA: VACCINES MARKET FOR LIVE ATTENUATED VACCINES, BY COUNTRY, 2021-2028 (USD BILLION)
  • 6.6 TOXOID VACCINES
    • 6.6.1 RISING PREVALENCE OF BACTERIAL INFECTIONS AMONG INFANTS AND CHILDREN TO DRIVE MARKET
    • TABLE 53 EXAMPLES OF TOXOID VACCINES
    • TABLE 54 VACCINES MARKET FOR TOXOID VACCINES, BY REGION, 2021-2028 (USD BILLION)
    • TABLE 55 NORTH AMERICA: VACCINES MARKET FOR TOXOID VACCINES, BY COUNTRY, 2021-2028 (USD BILLION)
    • TABLE 56 EUROPE: VACCINES MARKET FOR TOXOID VACCINES, BY COUNTRY, 2021-2028 (USD BILLION)
    • TABLE 57 ASIA PACIFIC: VACCINES MARKET FOR TOXOID VACCINES, BY COUNTRY, 2021-2028 (USD BILLION)
    • TABLE 58 LATIN AMERICA: VACCINES MARKET FOR TOXOID VACCINES, BY COUNTRY, 2021-2028 (USD BILLION)
  • 6.7 VIRAL VECTOR VACCINES
    • 6.7.1 INCREASING INVESTMENT IN NOVEL VACCINE DEVELOPMENT TO DRIVE MARKET
    • TABLE 59 VACCINES MARKET FOR VIRAL VECTOR VACCINES, BY REGION, 2021-2028 (USD BILLION)
    • TABLE 60 NORTH AMERICA: VACCINES MARKET FOR VIRAL VECTOR VACCINES, BY COUNTRY, 2021-2028 (USD BILLION)
    • TABLE 61 EUROPE: VACCINES MARKET FOR VIRAL VECTOR VACCINES, BY COUNTRY, 2021-2028 (USD BILLION)
    • TABLE 62 ASIA PACIFIC: VACCINES MARKET FOR VIRAL VECTOR VACCINES, BY COUNTRY, 2021-2028 (USD BILLION)
    • TABLE 63 LATIN AMERICA: VACCINES MARKET FOR VIRAL VECTOR VACCINES, BY COUNTRY, 2021-2028 (USD BILLION)
  • 6.8 M-RNA VACCINES
    • 6.8.1 INCREASING INVESTMENT IN M-RNA VACCINE DEVELOPMENT TO DRIVE MARKET
    • TABLE 64 VACCINES MARKET FOR M-RNA VACCINES, BY REGION, 2021-2028 (USD BILLION)
    • TABLE 65 NORTH AMERICA: VACCINES MARKET FOR M-RNA VACCINES, BY COUNTRY, 2021-2028 (USD BILLION)
    • TABLE 66 EUROPE: VACCINES MARKET FOR M-RNA VACCINES, BY COUNTRY, 2021-2028 (USD BILLION)
    • TABLE 67 ASIA PACIFIC: VACCINES MARKET FOR M-RNA VACCINES, BY COUNTRY, 2021-2028 (USD BILLION)
    • TABLE 68 LATIN AMERICA: VACCINES MARKET FOR M-RNA VACCINES, BY COUNTRY, 2021-2028 (USD BILLION)
  • 6.9 OTHER VACCINES
    • TABLE 69 VACCINES MARKET FOR OTHER VACCINES, BY REGION, 2021-2028 (USD BILLION)
    • TABLE 70 NORTH AMERICA: VACCINES MARKET FOR OTHER VACCINES, BY COUNTRY, 2021-2028 (USD BILLION)
    • TABLE 71 EUROPE: VACCINES MARKET FOR OTHER VACCINES, BY COUNTRY, 2021-2028 (USD BILLION)
    • TABLE 72 ASIA PACIFIC: VACCINES MARKET FOR OTHER VACCINES, BY COUNTRY, 2021-2028 (USD BILLION)
    • TABLE 73 LATIN AMERICA: VACCINES MARKET FOR OTHER VACCINES, BY COUNTRY, 2021-2028 (USD BILLION)

7 VACCINES MARKET, BY TYPE

  • 7.1 INTRODUCTION
    • TABLE 74 VACCINES MARKET, BY TYPE, 2021-2028 (USD BILLION)
  • 7.2 MONOVALENT VACCINES
    • 7.2.1 INCREASING INVESTMENT IN R&D AND RISING PREVALENCE OF INFECTIOUS DISEASES TO DRIVE MARKET
    • TABLE 75 EXAMPLES OF MONOVALENT VACCINES
    • TABLE 76 VACCINES MARKET FOR MONOVALENT VACCINES, BY REGION, 2021-2028 (USD BILLION)
    • TABLE 77 NORTH AMERICA: VACCINES MARKET FOR MONOVALENT VACCINES, BY COUNTRY, 2021-2028 (USD BILLION)
    • TABLE 78 EUROPE: VACCINES MARKET FOR MONOVALENT VACCINES, BY COUNTRY, 2021-2028 (USD BILLION)
    • TABLE 79 ASIA PACIFIC: VACCINES MARKET FOR MONOVALENT VACCINES, BY COUNTRY, 2021-2028 (USD BILLION)
    • TABLE 80 LATIN AMERICA: VACCINES MARKET FOR MONOVALENT VACCINES, BY COUNTRY, 2021-2028 (USD BILLION)
  • 7.3 MULTIVALENT VACCINES
    • 7.3.1 INCREASED NEED FOR IMMUNIZATION AND COST-EFFECTIVENESS TO DRIVE MARKET
    • TABLE 81 EXAMPLES OF MULTIVALENT VACCINES
    • TABLE 82 VACCINES MARKET FOR MULTIVALENT VACCINES, BY REGION, 2021-2028 (USD BILLION)
    • TABLE 83 NORTH AMERICA: VACCINES MARKET FOR MULTIVALENT VACCINES, BY COUNTRY, 2021-2028 (USD BILLION)
    • TABLE 84 EUROPE: VACCINES MARKET FOR MULTIVALENT VACCINES, BY COUNTRY, 2021-2028 (USD BILLION)
    • TABLE 85 ASIA PACIFIC: VACCINES MARKET FOR MULTIVALENT VACCINES, BY COUNTRY, 2021-2028 (USD BILLION)
    • TABLE 86 LATIN AMERICA: VACCINES MARKET FOR MULTIVALENT VACCINES, BY COUNTRY, 2021-2028 (USD BILLION)

8 VACCINES MARKET, BY DISEASE INDICATION

  • 8.1 INTRODUCTION
    • TABLE 87 VACCINES MARKET, BY DISEASE INDICATION, 2021-2028 (USD BILLION)
  • 8.2 PNEUMOCOCCAL DISEASE
    • 8.2.1 INCREASING INCIDENCE OF PNEUMONIA IN CHILDREN TO DRIVE MARKET
    • TABLE 88 LIST OF COMMERCIALLY AVAILABLE PNEUMOCOCCAL DISEASE VACCINES
    • TABLE 89 VACCINES MARKET FOR PNEUMOCOCCAL DISEASE, BY REGION, 2021-2028 (USD BILLION)
    • TABLE 90 NORTH AMERICA: VACCINES MARKET FOR PNEUMOCOCCAL DISEASE, BY COUNTRY, 2021-2028 (USD BILLION)
    • TABLE 91 EUROPE: VACCINES MARKET FOR PNEUMOCOCCAL DISEASE, BY COUNTRY, 2021-2028 (USD BILLION)
    • TABLE 92 ASIA PACIFIC: VACCINES MARKET FOR PNEUMOCOCCAL DISEASE, BY COUNTRY, 2021-2028 (USD BILLION)
    • TABLE 93 LATIN AMERICA: VACCINES MARKET FOR PNEUMOCOCCAL DISEASE, BY COUNTRY, 2021-2028 (USD BILLION)
  • 8.3 INFLUENZA
    • 8.3.1 RISING NEED FOR IMMUNIZATION AGAINST VIRAL INFECTIONS TO DRIVE MARKET
    • TABLE 94 LIST OF COMMERCIALLY AVAILABLE INFLUENZA VACCINES
    • TABLE 95 VACCINES MARKET FOR INFLUENZA, BY REGION, 2021-2028 (USD BILLION)
    • TABLE 96 NORTH AMERICA: VACCINES MARKET FOR INFLUENZA, BY COUNTRY, 2021-2028 (USD BILLION)
    • TABLE 97 EUROPE: VACCINES MARKET FOR INFLUENZA, BY COUNTRY, 2021-2028 (USD BILLION)
    • TABLE 98 ASIA PACIFIC: VACCINES MARKET FOR INFLUENZA, BY COUNTRY, 2021-2028 (USD BILLION)
    • TABLE 99 LATIN AMERICA: VACCINES MARKET FOR INFLUENZA, BY COUNTRY, 2021-2028 (USD BILLION)
  • 8.4 COMBINATION VACCINES
    • 8.4.1 GROWING DEMAND FOR ALL-IN-ONE VACCINE TO DRIVE MARKET
    • TABLE 100 LIST OF COMMERCIALLY AVAILABLE COMBINATION VACCINES
    • TABLE 101 VACCINES MARKET FOR COMBINATION VACCINES, BY REGION, 2021-2028 (USD BILLION)
    • TABLE 102 NORTH AMERICA: VACCINES MARKET FOR COMBINATION VACCINES, BY COUNTRY, 2021-2028 (USD BILLION)
    • TABLE 103 EUROPE: VACCINES MARKET FOR COMBINATION VACCINES, BY COUNTRY, 2021-2028 (USD BILLION)
    • TABLE 104 ASIA PACIFIC: VACCINES MARKET FOR COMBINATION VACCINES, BY COUNTRY, 2021-2028 (USD BILLION)
    • TABLE 105 LATIN AMERICA: VACCINES MARKET FOR COMBINATION VACCINES, BY COUNTRY, 2021-2028 (USD BILLION)
  • 8.5 HPV
    • 8.5.1 GROWING INCIDENCE OF SEXUALLY TRANSMITTED DISEASES TO DRIVE MARKET
    • TABLE 106 LIST OF COMMERCIALLY AVAILABLE HPV VACCINES
    • TABLE 107 VACCINES MARKET FOR HPV, BY REGION, 2021-2028 (USD BILLION)
    • TABLE 108 NORTH AMERICA: VACCINES MARKET FOR HPV, BY COUNTRY, 2021-2028 (USD BILLION)
    • TABLE 109 EUROPE: VACCINES MARKET FOR HPV, BY COUNTRY, 2021-2028 (USD BILLION)
    • TABLE 110 ASIA PACIFIC: VACCINES MARKET FOR HPV, BY COUNTRY, 2021-2028 (USD BILLION)
    • TABLE 111 LATIN AMERICA: VACCINES MARKET FOR HPV, BY COUNTRY, 2021-2028 (USD BILLION)
  • 8.6 MENINGOCOCCAL DISEASE
    • 8.6.1 INCREASING INITIATIVES BY GOVERNMENT AND NON-GOVERNMENT ORGANIZATIONS TO DRIVE MARKET
    • TABLE 112 LIST OF COMMERCIALLY AVAILABLE MENINGOCOCCAL DISEASE VACCINES
    • TABLE 113 VACCINES MARKET FOR MENINGOCOCCAL DISEASE, BY REGION, 2021-2028 (USD BILLION)
    • TABLE 114 NORTH AMERICA: VACCINES MARKET FOR MENINGOCOCCAL DISEASE, BY COUNTRY, 2021-2028 (USD BILLION)
    • TABLE 115 EUROPE: VACCINES MARKET FOR MENINGOCOCCAL DISEASE, BY COUNTRY, 2021-2028 (USD BILLION)
    • TABLE 116 ASIA PACIFIC: VACCINES MARKET FOR MENINGOCOCCAL DISEASE, BY COUNTRY, 2021-2028 (USD BILLION)
    • TABLE 117 LATIN AMERICA: VACCINES MARKET FOR MENINGOCOCCAL DISEASE, BY COUNTRY, 2021-2028 (USD BILLION)
  • 8.7 HERPES ZOSTER
    • 8.7.1 INCREASING INVESTMENT IN NOVEL VACCINE DEVELOPMENT TO DRIVE MARKET
    • TABLE 118 VACCINES MARKET FOR HERPES ZOSTER, BY REGION, 2021-2028 (USD BILLION)
    • TABLE 119 NORTH AMERICA: VACCINES MARKET FOR HERPES ZOSTER, BY COUNTRY, 2021-2028 (USD BILLION)
    • TABLE 120 EUROPE: VACCINES MARKET FOR HERPES ZOSTER, BY COUNTRY, 2021-2028 (USD BILLION)
    • TABLE 121 ASIA PACIFIC: VACCINES MARKET FOR HERPES ZOSTER, BY COUNTRY, 2021-2028 (USD BILLION)
    • TABLE 122 LATIN AMERICA: VACCINES MARKET FOR HERPES ZOSTER, BY COUNTRY, 2021-2028 (USD BILLION)
  • 8.8 ROTAVIRUS
    • 8.8.1 GROWING FOCUS OF GOVERNMENT AND NON-GOVERNMENT BODIES ON ROTAVIRUS PREVENTION TO DRIVE MARKET
    • TABLE 123 LIST OF COMMERCIALLY AVAILABLE ROTAVIRUS VACCINES
    • TABLE 124 VACCINES MARKET FOR ROTAVIRUS, BY REGION, 2021-2028 (USD BILLION)
    • TABLE 125 NORTH AMERICA: VACCINES MARKET FOR ROTAVIRUS, BY COUNTRY, 2021-2028 (USD BILLION)
    • TABLE 126 EUROPE: VACCINES MARKET FOR ROTAVIRUS, BY COUNTRY, 2021-2028 (USD BILLION)
    • TABLE 127 ASIA PACIFIC: VACCINES MARKET FOR ROTAVIRUS, BY COUNTRY, 2021-2028 (USD BILLION)
    • TABLE 128 LATIN AMERICA: VACCINES MARKET FOR ROTAVIRUS, BY COUNTRY, 2021-2028 (USD BILLION)
  • 8.9 MMR
    • 8.9.1 RISING INCIDENCE OF MEASLES, MUMPS, AND RUBELLA TO DRIVE MARKET
    • TABLE 129 LIST OF COMMERCIALLY AVAILABLE MMR VACCINES
    • TABLE 130 VACCINES MARKET FOR MMR, BY REGION, 2021-2028 (USD BILLION)
    • TABLE 131 NORTH AMERICA: VACCINES MARKET FOR MMR, BY COUNTRY, 2021-2028 (USD BILLION)
    • TABLE 132 EUROPE: VACCINES MARKET FOR MMR, BY COUNTRY, 2021-2028 (USD BILLION)
    • TABLE 133 ASIA PACIFIC: VACCINES MARKET FOR MMR, BY COUNTRY, 2021-2028 (USD BILLION)
    • TABLE 134 LATIN AMERICA: VACCINES MARKET FOR MMR, BY COUNTRY, 2021-2028 (USD BILLION)
  • 8.10 VARICELLA
    • 8.10.1 INCREASING PROMOTION OF IMMUNIZATION PROGRAMS TO DRIVE MARKET
    • TABLE 135 LIST OF COMMERCIALLY AVAILABLE VARICELLA VACCINES
    • TABLE 136 VACCINES MARKET FOR VARICELLA, BY REGION, 2021-2028 (USD BILLION)
    • TABLE 137 NORTH AMERICA: VACCINES MARKET FOR VARICELLA, BY COUNTRY, 2021-2028 (USD BILLION)
    • TABLE 138 EUROPE: VACCINES MARKET FOR VARICELLA, BY COUNTRY, 2021-2028 (USD BILLION)
    • TABLE 139 ASIA PACIFIC: VACCINES MARKET FOR VARICELLA, BY COUNTRY, 2021-2028 (USD BILLION)
    • TABLE 140 LATIN AMERICA: VACCINES MARKET FOR VARICELLA, BY COUNTRY, 2021-2028 (USD BILLION)
  • 8.11 HEPATITIS
    • 8.11.1 LOW SOCIO-ECONOMIC STANDARDS OF LIVING AND HIGH CONTAMINATION IN DRINKING WATER TO DRIVE MARKET
    • TABLE 141 LIST OF COMMERCIALLY AVAILABLE HEPATITIS VACCINES
    • TABLE 142 VACCINES MARKET FOR HEPATITIS, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 143 NORTH AMERICA: VACCINES MARKET FOR HEPATITIS, BY COUNTRY, 2021-2028 (USD BILLION)
    • TABLE 144 EUROPE: VACCINES MARKET FOR HEPATITIS, BY COUNTRY, 2021-2028 (USD BILLION)
    • TABLE 145 ASIA PACIFIC: VACCINES MARKET FOR HEPATITIS, BY COUNTRY, 2021-2028 (USD BILLION)
    • TABLE 146 LATIN AMERICA: VACCINES MARKET FOR HEPATITIS, BY COUNTRY, 2021-2028 (USD BILLION)
  • 8.12 DTP
    • 8.12.1 INCREASED OCCURRENCE OF DIPHTHERIA, TETANUS, AND PERTUSSIS IN EMERGING ECONOMIES TO DRIVE MARKET
    • TABLE 147 LIST OF COMMERCIALLY AVAILABLE DTP VACCINES
    • TABLE 148 VACCINES MARKET FOR DTP, BY REGION, 2021-2028 (USD BILLION)
    • TABLE 149 NORTH AMERICA: VACCINES MARKET FOR DTP, BY COUNTRY, 2021-2028 (USD BILLION)
    • TABLE 150 EUROPE: VACCINES MARKET FOR DTP, BY COUNTRY, 2021-2028 (USD BILLION)
    • TABLE 151 ASIA PACIFIC: VACCINES MARKET FOR DTP, BY COUNTRY, 2021-2028 (USD BILLION)
    • TABLE 152 LATIN AMERICA: VACCINES MARKET FOR DTP, BY COUNTRY, 2021-2028 (USD BILLION)
  • 8.13 POLIO
    • 8.13.1 INCREASING GOVERNMENT INITIATIVES AND IMMUNIZATION PROGRAMS TO DRIVE MARKET
    • TABLE 153 VACCINES MARKET FOR POLIO, BY REGION, 2021-2028 (USD BILLION)
    • TABLE 154 NORTH AMERICA: VACCINES MARKET FOR POLIO, BY COUNTRY, 2021-2028 (USD BILLION)
    • TABLE 155 EUROPE: VACCINES MARKET FOR POLIO, BY COUNTRY, 2021-2028 (USD BILLION)
    • TABLE 156 ASIA PACIFIC: VACCINES MARKET FOR POLIO, BY COUNTRY, 2021-2028 (USD BILLION)
    • TABLE 157 LATIN AMERICA: VACCINES MARKET FOR POLIO, BY COUNTRY, 2021-2028 (USD BILLION)
  • 8.14 OTHER DISEASE INDICATIONS
    • FIGURE 31 NUMBER OF COVID-19 CASES IN US, 2020-2023
    • TABLE 158 LIST OF COMMERCIALLY AVAILABLE VACCINES FOR OTHER DISEASE INDICATIONS
    • TABLE 159 VACCINES MARKET FOR OTHER DISEASE INDICATIONS, BY REGION, 2021-2028 (USD BILLION)
    • TABLE 160 NORTH AMERICA: VACCINES MARKET FOR OTHER DISEASE INDICATIONS, BY COUNTRY, 2021-2028 (USD BILLION)
    • TABLE 161 EUROPE: VACCINES MARKET FOR OTHER DISEASE INDICATIONS, BY COUNTRY, 2021-2028 (USD BILLION)
    • TABLE 162 ASIA PACIFIC: VACCINES MARKET FOR OTHER DISEASE INDICATIONS, BY COUNTRY, 2021-2028 (USD BILLION)
    • TABLE 163 LATIN AMERICA: VACCINES MARKET FOR OTHER DISEASE INDICATIONS, BY COUNTRY, 2021-2028 (USD BILLION)

9 VACCINES MARKET, BY ROUTE OF ADMINISTRATION

  • 9.1 INTRODUCTION
    • TABLE 164 VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD BILLION)
  • 9.2 INTRAMUSCULAR AND SUBCUTANEOUS ADMINISTRATION
    • 9.2.1 EASIER ABSORPTION INTO BLOODSTREAM AND BETTER IMMUNE RESPONSE TO DRIVE MARKET
    • TABLE 165 ADVANTAGES AND DISADVANTAGES OF INTRAMUSCULAR AND SUBCUTANEOUS ADMINISTRATION
    • TABLE 166 VACCINES MARKET FOR INTRAMUSCULAR AND SUBCUTANEOUS ADMINISTRATION, BY REGION, 2021-2028 (USD BILLION)
    • TABLE 167 NORTH AMERICA: VACCINES MARKET FOR INTRAMUSCULAR AND SUBCUTANEOUS ADMINISTRATION, BY COUNTRY, 2021-2028 (USD BILLION)
    • TABLE 168 EUROPE: VACCINES MARKET FOR INTRAMUSCULAR AND SUBCUTANEOUS ADMINISTRATION, BY COUNTRY, 2021-2028 (USD BILLION)
    • TABLE 169 ASIA PACIFIC: VACCINES MARKET FOR INTRAMUSCULAR AND SUBCUTANEOUS ADMINISTRATION, BY COUNTRY, 2021-2028 (USD BILLION)
    • TABLE 170 LATIN AMERICA: VACCINES MARKET FOR INTRAMUSCULAR AND SUBCUTANEOUS ADMINISTRATION, BY COUNTRY, 2021-2028 (USD BILLION)
  • 9.3 ORAL ADMINISTRATION
    • 9.3.1 EASE OF ADMINISTRATION AND REDUCED RISK OF BLOOD-TRANSMITTED INFECTIONS TO DRIVE MARKET
    • TABLE 171 VACCINES MARKET FOR ORAL ADMINISTRATION, BY REGION, 2021-2028 (USD BILLION)
    • TABLE 172 NORTH AMERICA: VACCINES MARKET FOR ORAL ADMINISTRATION, BY COUNTRY, 2021-2028 (USD BILLION)
    • TABLE 173 EUROPE: VACCINES MARKET FOR ORAL ADMINISTRATION, BY COUNTRY, 2021-2028 (USD BILLION)
    • TABLE 174 ASIA PACIFIC: VACCINES MARKET FOR ORAL ADMINISTRATION, BY COUNTRY, 2021-2028 (USD BILLION)
    • TABLE 175 LATIN AMERICA: VACCINES MARKET FOR ORAL ADMINISTRATION, BY COUNTRY, 2021-2028 (USD BILLION)
  • 9.4 OTHER ROUTES OF ADMINISTRATION
    • TABLE 176 VACCINES MARKET FOR OTHER ROUTES OF ADMINISTRATION, BY REGION, 2021-2028 (USD BILLION)
    • TABLE 177 NORTH AMERICA: VACCINES MARKET FOR OTHER ROUTES OF ADMINISTRATION, BY COUNTRY, 2021-2028 (USD BILLION)
    • TABLE 178 EUROPE: VACCINES MARKET FOR OTHER ROUTES OF ADMINISTRATION, BY COUNTRY, 2021-2028 (USD BILLION)
    • TABLE 179 ASIA PACIFIC: VACCINES MARKET FOR OTHER ROUTES OF ADMINISTRATION, BY COUNTRY, 2021-2028 (USD BILLION)
    • TABLE 180 LATIN AMERICA: VACCINES MARKET FOR OTHER ROUTES OF ADMINISTRATION, BY COUNTRY, 2021-2028 (USD BILLION)

10 VACCINES MARKET, BY END USER

  • 10.1 INTRODUCTION
    • TABLE 181 VACCINES MARKET, BY END USER, 2021-2028 (USD BILLION)
  • 10.2 PEDIATRIC VACCINES
    • 10.2.1 INCREASED INITIATIVES BY GOVERNMENT AND NON-GOVERNMENT BODIES TO DRIVE MARKET
    • TABLE 182 VACCINES MARKET FOR PEDIATRIC VACCINES, BY REGION, 2021-2028 (USD BILLION)
    • TABLE 183 NORTH AMERICA: VACCINES MARKET FOR PEDIATRIC VACCINES, BY COUNTRY, 2021-2028 (USD BILLION)
    • TABLE 184 EUROPE: VACCINES MARKET FOR PEDIATRIC VACCINES, BY COUNTRY, 2021-2028 (USD BILLION)
    • TABLE 185 ASIA PACIFIC: VACCINES MARKET FOR PEDIATRIC VACCINES, BY COUNTRY, 2021-2028 (USD BILLION)
    • TABLE 186 LATIN AMERICA: VACCINES MARKET FOR PEDIATRIC VACCINES, BY COUNTRY, 2021-2028 (USD BILLION)
  • 10.3 ADULT VACCINES
    • 10.3.1 ADULT VACCINES SEGMENT TO COMMAND LARGER MARKET SHARE DURING FORECAST PERIOD
    • TABLE 187 VACCINES MARKET FOR ADULT VACCINES, BY REGION, 2021-2028 (USD BILLION)
    • TABLE 188 NORTH AMERICA: VACCINES MARKET FOR ADULT VACCINES, BY COUNTRY, 2021-2028 (USD BILLION)
    • TABLE 189 EUROPE: VACCINES MARKET FOR ADULT VACCINES, BY COUNTRY, 2021-2028 (USD BILLION)
    • TABLE 190 ASIA PACIFIC: VACCINES MARKET FOR ADULT VACCINES, BY COUNTRY, 2021-2028 (USD BILLION)
    • TABLE 191 LATIN AMERICA: VACCINES MARKET FOR ADULT VACCINES, BY COUNTRY, 2021-2028 (USD BILLION)

11 VACCINES MARKET, BY REGION

  • 11.1 INTRODUCTION
    • TABLE 192 VACCINES MARKET, BY REGION, 2021-2028 (USD BILLION)
  • 11.2 NORTH AMERICA
    • FIGURE 32 NORTH AMERICA: VACCINES MARKET SNAPSHOT
    • TABLE 193 NORTH AMERICA: VACCINES MARKET, BY COUNTRY, 2021-2028 (USD BILLION)
    • TABLE 194 NORTH AMERICA: VACCINES MARKET, BY TECHNOLOGY, 2021-2028 (USD BILLION)
    • TABLE 195 NORTH AMERICA: VACCINES MARKET, BY TYPE, 2021-2028 (USD BILLION)
    • TABLE 196 NORTH AMERICA: VACCINES MARKET, BY DISEASE INDICATION, 2021-2028 (USD BILLION)
    • TABLE 197 NORTH AMERICA: VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD BILLION)
    • TABLE 198 NORTH AMERICA: VACCINES MARKET, BY END USER, 2021-2028 (USD BILLION)
  • 11.3 NORTH AMERICA: RECESSION IMPACT
    • 11.3.1 US
      • 11.3.1.1 US to dominate North American vaccines market during forecast period
    • TABLE 199 US: VACCINES MARKET, BY TECHNOLOGY, 2021-2028 (USD BILLION)
    • TABLE 200 US: VACCINES MARKET, BY TYPE, 2021-2028 (USD BILLION)
    • TABLE 201 US: VACCINES MARKET, BY DISEASE INDICATION, 2021-2028 (USD BILLION)
    • TABLE 202 US: VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD BILLION)
    • TABLE 203 US: VACCINES MARKET, BY END USER, 2021-2028 (USD BILLION)
    • 11.3.2 CANADA
      • 11.3.2.1 High incidence of infectious diseases to drive market
    • TABLE 204 CANADA: VACCINES MARKET, BY TECHNOLOGY, 2021-2028 (USD BILLION)
    • TABLE 205 CANADA: VACCINES MARKET, BY TYPE, 2021-2028 (USD BILLION)
    • TABLE 206 CANADA: VACCINES MARKET, BY DISEASE INDICATION, 2021-2028 (USD BILLION)
    • TABLE 207 CANADA: VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD BILLION)
    • TABLE 208 CANADA: VACCINES MARKET, BY END USER, 2021-2028 (USD BILLION)
  • 11.4 EUROPE
    • TABLE 209 EUROPE: VACCINES MARKET, BY COUNTRY, 2021-2028 (USD BILLION)
    • TABLE 210 EUROPE: VACCINES MARKET, BY TECHNOLOGY, 2021-2028 (USD BILLION)
    • TABLE 211 EUROPE: VACCINES MARKET, BY TYPE, 2021-2028 (USD BILLION)
    • TABLE 212 EUROPE: VACCINES MARKET, BY DISEASE INDICATION, 2021-2028 (USD BILLION)
    • TABLE 213 EUROPE VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD BILLION)
    • TABLE 214 EUROPE: VACCINES MARKET, BY END USER, 2021-2028 (USD BILLION)
  • 11.5 EUROPE: RECESSION IMPACT
    • 11.5.1 GERMANY
      • 11.5.1.1 Significant R&D investments and growing biotechnology industry to drive market
    • TABLE 215 GERMANY: VACCINES MARKET, BY TECHNOLOGY, 2021-2028 (USD BILLION)
    • TABLE 216 GERMANY: VACCINES MARKET, BY TYPE, 2021-2028 (USD BILLION)
    • TABLE 217 GERMANY: VACCINES MARKET, BY DISEASE INDICATION, 2021-2028 (USD BILLION)
    • TABLE 218 GERMANY: VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD BILLION)
    • TABLE 219 GERMANY: VACCINES MARKET, BY END USER, 2021-2028 (USD BILLION)
    • 11.5.2 UK
      • 11.5.2.1 Launch of new products and increased funding by government and non-government organizations to drive market
    • TABLE 220 UK: VACCINES MARKET, BY TECHNOLOGY, 2021-2028 (USD BILLION)
    • TABLE 221 UK: VACCINES MARKET, BY TYPE, 2021-2028 (USD BILLION)
    • TABLE 222 UK: VACCINES MARKET, BY DISEASE INDICATION, 2021-2028 (USD BILLION)
    • TABLE 223 UK: VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD BILLION)
    • TABLE 224 UK: VACCINES MARKET, BY END USER, 2021-2028 (USD BILLION)
    • 11.5.3 FRANCE
      • 11.5.3.1 Favorable government initiatives for mass immunization to drive market
    • TABLE 225 FRANCE: VACCINES MARKET, BY TECHNOLOGY, 2021-2028 (USD BILLION)
    • TABLE 226 FRANCE: VACCINES MARKET, BY TYPE, 2021-2028 (USD BILLION)
    • TABLE 227 FRANCE: VACCINES MARKET, BY DISEASE INDICATION, 2021-2028 (USD BILLION)
    • TABLE 228 FRANCE: VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD BILLION)
    • TABLE 229 FRANCE: VACCINES MARKET, BY END USER, 2021-2028 (USD BILLION)
    • 11.5.4 ITALY
      • 11.5.4.1 Higher investments by companies for increased production capacities to drive market
    • TABLE 230 ITALY: VACCINES MARKET, BY TECHNOLOGY, 2021-2028 (USD BILLION)
    • TABLE 231 ITALY: VACCINES MARKET, BY TYPE, 2021-2028 (USD BILLION)
    • TABLE 232 ITALY: VACCINES MARKET, BY DISEASE INDICATION, 2021-2028 (USD BILLION)
    • TABLE 233 TALY: VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD BILLION)
    • TABLE 234 ITALY: VACCINES MARKET, BY END USER, 2021-2028 (USD BILLION)
    • 11.5.5 SPAIN
      • 11.5.5.1 Rising investments in vaccine development by private organizations to drive market
    • TABLE 235 SPAIN: VACCINES MARKET, BY TECHNOLOGY, 2021-2028 (USD BILLION)
    • TABLE 236 SPAIN: VACCINES MARKET, BY TYPE, 2021-2028 (USD BILLION)
    • TABLE 237 SPAIN: VACCINES MARKET, BY DISEASE INDICATION, 2021-2028 (USD BILLION)
    • TABLE 238 SPAIN: VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD BILLION)
    • TABLE 239 SPAIN: VACCINES MARKET, BY END USER, 2021-2028 (USD BILLION)
    • 11.5.6 REST OF EUROPE
    • TABLE 240 REST OF EUROPE: VACCINES MARKET, BY TECHNOLOGY, 2021-2028 (USD BILLION)
    • TABLE 241 REST OF EUROPE: VACCINES MARKET, BY TYPE, 2021-2028 (USD BILLION)
    • TABLE 242 REST OF EUROPE: VACCINES MARKET, BY DISEASE INDICATION, 2021-2028 (USD BILLION)
    • TABLE 243 REST OF EUROPE: VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD BILLION)
    • TABLE 244 REST OF EUROPE: VACCINES MARKET, BY END USER, 2021-2028 (USD BILLION)
  • 11.6 ASIA PACIFIC
    • FIGURE 33 ASIA PACIFIC: VACCINES MARKET SNAPSHOT
    • TABLE 245 ASIA PACIFIC: VACCINES MARKET, BY COUNTRY, 2021-2028 (USD BILLION)
    • TABLE 246 ASIA PACIFIC: VACCINES MARKET, BY TECHNOLOGY, 2021-2028 (USD BILLION)
    • TABLE 247 ASIA PACIFIC: VACCINES MARKET, BY TYPE, 2021-2028 (USD BILLION)
    • TABLE 248 ASIA PACIFIC: VACCINES MARKET, BY DISEASE INDICATION, 2021-2028 (USD BILLION)
    • TABLE 249 ASIA PACIFIC: VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD BILLION)
    • TABLE 250 ASIA PACIFIC: VACCINES MARKET, BY END USER, 2021-2028 (USD BILLION)
  • 11.7 ASIA PACIFIC: RECESSION IMPACT
    • 11.7.1 JAPAN
      • 11.7.1.1 Increasing government initiatives for improving quality of vaccines to drive market
    • TABLE 251 JAPAN: VACCINES MARKET, BY TECHNOLOGY, 2021-2028 (USD BILLION)
    • TABLE 252 JAPAN: VACCINES MARKET, BY TYPE, 2021-2028 (USD BILLION)
    • TABLE 253 JAPAN: VACCINES MARKET, BY DISEASE INDICATION, 2021-2028 (USD BILLION)
    • TABLE 254 JAPAN: VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD BILLION)
    • TABLE 255 JAPAN: VACCINES MARKET, BY END USER, 2021-2028 (USD BILLION)
    • 11.7.2 SOUTH KOREA
      • 11.7.2.1 Strong government strategies for improved vaccine hubs to drive market
    • TABLE 256 SOUTH KOREA: VACCINES MARKET, BY TECHNOLOGY, 2021-2028 (USD BILLION)
    • TABLE 257 SOUTH KOREA: VACCINES MARKET, BY TYPE, 2021-2028 (USD BILLION)
    • TABLE 258 SOUTH KOREA: VACCINES MARKET, BY DISEASE INDICATION, 2021-2028 (USD BILLION)
    • TABLE 259 SOUTH KOREA: VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD BILLION)
    • TABLE 260 SOUTH KOREA: VACCINES MARKET, BY END USER, 2021-2028 (USD BILLION)
    • 11.7.3 CHINA
      • 11.7.3.1 Growing investments in biotechnology sector to drive market
    • TABLE 261 CHINA: VACCINES MARKET, BY TECHNOLOGY, 2021-2028 (USD BILLION)
    • TABLE 262 CHINA: VACCINES MARKET, BY TYPE, 2021-2028 (USD BILLION)
    • TABLE 263 CHINA: VACCINES MARKET, BY DISEASE INDICATION, 2021-2028 (USD BILLION)
    • TABLE 264 CHINA: VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD BILLION)
    • TABLE 265 CHINA: VACCINES MARKET, BY END USER, 2021-2028 (USD BILLION)
    • 11.7.4 INDIA
      • 11.7.4.1 Increasing government initiatives and development of new and improved vaccines to drive market
    • TABLE 266 INDIA: VACCINES MARKET, BY TECHNOLOGY, 2021-2028 (USD BILLION)
    • TABLE 267 INDIA: VACCINES MARKET, BY TYPE, 2021-2028 (USD BILLION)
    • TABLE 268 INDIA: VACCINES MARKET, BY DISEASE INDICATION, 2021-2028 (USD BILLION)
    • TABLE 269 INDIA: VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD BILLION)
    • TABLE 270 INDIA: VACCINES MARKET, BY END USER, 2021-2028 (USD BILLION)
    • 11.7.5 REST OF ASIA PACIFIC
    • TABLE 271 REST OF ASIA PACIFIC: VACCINES MARKET, BY TECHNOLOGY, 2021-2028 (USD BILLION)
    • TABLE 272 REST OF ASIA PACIFIC: VACCINES MARKET, BY TYPE, 2021-2028 (USD BILLION)
    • TABLE 273 REST OF ASIA PACIFIC: VACCINES MARKET, BY DISEASE INDICATION, 2021-2028 (USD BILLION)
    • TABLE 274 REST OF ASIA PACIFIC: VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD BILLION)
    • TABLE 275 REST OF ASIA PACIFIC: VACCINES MARKET, BY END USER, 2021-2028 (USD BILLION)
  • 11.8 LATIN AMERICA
    • TABLE 276 LATIN AMERICA: VACCINES MARKET, BY COUNTRY, 2021-2028 (USD BILLION)
    • TABLE 277 LATIN AMERICA: VACCINES MARKET, BY TECHNOLOGY, 2021-2028 (USD BILLION)
    • TABLE 278 LATIN AMERICA: VACCINES MARKET, BY TYPE, 2021-2028 (USD BILLION)
    • TABLE 279 LATIN AMERICA: VACCINES MARKET, BY DISEASE INDICATION, 2021-2028 (USD BILLION)
    • TABLE 280 LATIN AMERICA: VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD BILLION)
    • TABLE 281 LATIN AMERICA: VACCINES MARKET, BY END USER, 2021-2028 (USD BILLION)
  • 11.9 LATIN AMERICA: RECESSION IMPACT
    • 11.9.1 BRAZIL
      • 11.9.1.1 Rising focus on immunization programs by government and non-government bodies to drive market
    • TABLE 282 BRAZIL: VACCINES MARKET, BY TECHNOLOGY, 2021-2028 (USD BILLION)
    • TABLE 283 BRAZIL: VACCINES MARKET, BY TYPE, 2021-2028 (USD BILLION)
    • TABLE 284 BRAZIL: VACCINES MARKET, BY DISEASE INDICATION, 2021-2028 (USD BILLION)
    • TABLE 285 BRAZIL: VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD BILLION)
    • TABLE 286 BRAZIL: VACCINES MARKET, BY END USER, 2021-2028 (USD BILLION)
    • 11.9.2 MEXICO
      • 11.9.2.1 Presence of well-trained health professionals and ethnically varied population base for clinical trials to drive market
    • TABLE 287 MEXICO: VACCINES MARKET, BY TECHNOLOGY, 2021-2028 (USD BILLION)
    • TABLE 288 MEXICO: VACCINES MARKET, BY TYPE, 2021-2028 (USD BILLION)
    • TABLE 289 MEXICO: VACCINES MARKET, BY DISEASE INDICATION, 2021-2028 (USD BILLION)
    • TABLE 290 MEXICO: VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD BILLION)
    • TABLE 291 MEXICO: VACCINES MARKET, BY END USER, 2021-2028 (USD BILLION)
    • 11.9.3 REST OF LATIN AMERICA
    • TABLE 292 REST OF LATIN AMERICA: VACCINES MARKET, BY TECHNOLOGY, 2021-2028 (USD BILLION)
    • TABLE 293 REST OF LATIN AMERICA: VACCINES MARKET, BY TYPE, 2021-2028 (USD BILLION)
    • TABLE 294 REST OF LATIN AMERICA: VACCINES MARKET, BY DISEASE INDICATION, 2021-2028 (USD BILLION)
    • TABLE 295 REST OF LATIN AMERICA: VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD BILLION)
    • TABLE 296 REST OF LATIN AMERICA: VACCINES MARKET, BY END USER, 2021-2028 (USD BILLION)
  • 11.10 MIDDLE EAST & AFRICA
    • 11.10.1 MIDDLE EAST
      • 11.10.1.1 Increasing prevalence of infectious diseases to drive market
    • TABLE 297 MIDDLE EAST: VACCINES MARKET, BY TECHNOLOGY, 2021-2028 (USD BILLION)
    • TABLE 298 MIDDLE EAST: VACCINES MARKET, BY TYPE, 2021-2028 (USD BILLION)
    • TABLE 299 MIDDLE EAST: VACCINES MARKET, BY DISEASE INDICATION, 2021-2028 (USD BILLION)
    • TABLE 300 MIDDLE EAST: VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD BILLION)
    • TABLE 301 MIDDLE EAST: VACCINES MARKET, BY END USER, 2021-2028 (USD BILLION)
    • 11.10.2 AFRICA
      • 11.10.2.1 Availability of funds and grants from developed economies to drive market
    • TABLE 302 AFRICA: VACCINES MARKET, BY TECHNOLOGY, 2021-2028 (USD BILLION)
    • TABLE 303 AFRICA: VACCINES MARKET, BY TYPE, 2021-2028 (USD BILLION)
    • TABLE 304 AFRICA: VACCINES MARKET, BY DISEASE INDICATION, 2021-2028 (USD BILLION)
    • TABLE 305 AFRICA: VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD BILLION)
    • TABLE 306 AFRICA: VACCINES MARKET, BY END USER, 2021-2028 (USD BILLION)
    • 11.10.3 MIDDLE EAST & AFRICA: RECESSION IMPACT

12 COMPETITIVE LANDSCAPE

  • 12.1 INTRODUCTION
  • 12.2 KEY STRATEGIES/RIGHT TO WIN
  • 12.3 STRATEGIES OF KEY PLAYERS IN VACCINES MARKET
    • TABLE 307 STRATEGIES ADOPTED BY MAJOR PLAYERS IN VACCINES MARKET
  • 12.4 REVENUE SHARE ANALYSIS
    • FIGURE 34 REVENUE SHARE ANALYSIS, 2020-2022
  • 12.5 MARKET SHARE ANALYSIS
    • FIGURE 35 MARKET SHARE ANALYSIS OF MAJOR PLAYERS IN VACCINES MARKET, 2022
    • TABLE 308 DEGREE OF COMPETITION: VACCINES MARKET
  • 12.6 COMPANY EVALUATION MATRIX
    • 12.6.1 STARS
    • 12.6.2 EMERGING LEADERS
    • 12.6.3 PERVASIVE PLAYERS
    • 12.6.4 PARTICIPANTS
    • FIGURE 36 COMPANY EVALUATION MATRIX, 2022
    • 12.6.5 COMPANY FOOTPRINT
      • 12.6.5.1 Product footprint
      • 12.6.5.2 Regional footprint
  • 12.7 START-UP/SME EVALUATION MATRIX
    • 12.7.1 PROGRESSIVE COMPANIES
    • 12.7.2 RESPONSIVE COMPANIES
    • 12.7.3 DYNAMIC COMPANIES
    • 12.7.4 STARTING BLOCKS
    • FIGURE 37 START-UP/SME EVALUATION MATRIX, 2022
    • 12.7.5 COMPETITIVE BENCHMARKING
    • TABLE 309 DETAILED LIST OF KEY START-UPS/SMES
    • TABLE 310 TECHNOLOGY AND REGIONAL BENCHMARKING FOR START-UPS/SMES
  • 12.8 COMPETITIVE SCENARIOS AND TRENDS
    • 12.8.1 KEY PRODUCT LAUNCHES AND APPROVALS
    • TABLE 311 KEY PRODUCT LAUNCHES AND APPROVALS, JANUARY 2021-SEPTEMBER 2023
    • 12.8.2 KEY DEALS
    • TABLE 312 KEY DEALS, JANUARY 2021-SEPTEMBER 2023
    • 12.8.3 OTHER KEY DEVELOPMENTS
    • TABLE 313 OTHER KEY DEVELOPMENTS, JANUARY 2021-SEPTEMBER 2023

13 COMPANY PROFILES

  • (Business overview, Products/Services/Solutions offered, Recent Developments, MNM view)**
  • 13.1 KEY PLAYERS
    • 13.1.1 PFIZER INC.
    • TABLE 314 PFIZER INC.: COMPANY OVERVIEW
    • FIGURE 38 PFIZER INC.: COMPANY SNAPSHOT (2022)
    • 13.1.2 MERCK & CO., INC.
    • TABLE 315 MERCK & CO., INC.: COMPANY OVERVIEW
    • FIGURE 39 MERCK & CO. INC.: COMPANY SNAPSHOT (2022)
    • 13.1.3 GSK PLC
    • TABLE 316 GSK PLC: COMPANY OVERVIEW
    • FIGURE 40 GSK PLC: COMPANY SNAPSHOT (2022)
    • 13.1.4 SANOFI
    • TABLE 317 SANOFI: COMPANY OVERVIEW
    • FIGURE 41 SANOFI: COMPANY SNAPSHOT (2022)
    • 13.1.5 CSL
    • TABLE 318 CSL: COMPANY OVERVIEW
    • FIGURE 42 CSL: COMPANY SNAPSHOT (2022)
    • 13.1.6 EMERGENT
    • TABLE 319 EMERGENT: COMPANY OVERVIEW
    • FIGURE 43 EMERGENT: COMPANY SNAPSHOT (2022)
    • 13.1.7 JOHNSON & JOHNSON SERVICES, INC.
    • TABLE 320 JOHNSON & JOHNSON SERVICES INC.: COMPANY OVERVIEW
    • FIGURE 44 JOHNSON & JOHNSON SERVICES INC: COMPANY SNAPSHOT (2022)
    • 13.1.8 ASTRAZENECA
    • TABLE 321 ASTRAZENECA: COMPANY OVERVIEW
    • FIGURE 45 ASTRAZENECA: COMPANY SNAPSHOT (2022)
    • 13.1.9 SERUM INSTITUTE OF INDIA PVT., LTD.
    • TABLE 322 SERUM INSTITUTE OF INDIA PVT., LTD.: COMPANY OVERVIEW
    • 13.1.10 BAVARIAN NORDIC
    • TABLE 323 BAVARIAN NORDIC: COMPANY OVERVIEW
    • FIGURE 46 BAVARIAN NORDIC: COMPANY SNAPSHOT (2022)
    • 13.1.11 MITSUBISHI TANABE PHARMA CORPORATION
    • TABLE 324 MITSUBISHI TANABE PHARMA CORPORATION: COMPANY OVERVIEW
    • 13.1.12 DAIICHI SANKYO COMPANY, LIMITED
    • TABLE 325 DAIICHI SANKYO COMPANY, LIMITED: COMPANY OVERVIEW
    • FIGURE 47 DAIICHI SANKYO COMPANY, LIMITED: COMPANY SNAPSHOT (2022)
    • 13.1.13 PANACEA BIOTEC
    • TABLE 326 PANACEA BIOTEC: COMPANY OVERVIEW
    • FIGURE 48 PANACEA BIOTEC: COMPANY SNAPSHOT (2022)
    • 13.1.14 BIOLOGICAL E LIMITED
    • TABLE 327 BIOLOGICAL E LIMITED: COMPANY OVERVIEW
    • 13.1.15 BHARAT BIOTECH
    • TABLE 328 BHARAT BIOTECH: COMPANY OVERVIEW
    • 13.1.16 NOVAVAX
    • TABLE 329 NOVAVAX: COMPANY OVERVIEW
    • FIGURE 49 NOVAVAX, INC.: COMPANY SNAPSHOT (2022)
    • 13.1.17 INOVIO PHARMACEUTICALS
    • TABLE 330 INOVIO PHARMACEUTICALS: COMPANY OVERVIEW
    • FIGURE 50 INOVIO PHARMACEUTICALS: COMPANY SNAPSHOT (2022)
  • 13.2 OTHER PLAYERS
    • 13.2.1 SINOVAC
    • 13.2.2 INCEPTA PHARMACEUTICALS LTD.
    • 13.2.3 VALNEVA SE
    • 13.2.4 VBI VACCINES INC.
    • 13.2.5 BIO FARMA
    • 13.2.6 FSUE NPO MICROGEN
    • 13.2.7 ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.
    • 13.2.8 INDIAN IMMUNOLOGICALS LIMITED
  • *Details on Business overview, Products/Services/Solutions offered, Recent Developments, MNM view might not be captured in case of unlisted companies.

14 APPENDIX

  • 14.1 DISCUSSION GUIDE
  • 14.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
  • 14.3 CUSTOMIZATION OPTIONS
  • 14.4 RELATED REPORTS
  • 14.5 AUTHOR DETAILS
Show more
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Contact Us +1-866-353-3335
Hi, how can we help?
Contact us!